With COVID’s windfall over and blockbuster patents expiring, Pfizer is looking for a comeback with its newly built obesity ...

Quick ReadPfizer (PFE) yields nearly 7%, but free cash flow covered only 93% of dividends in 2025, leaving a dangerously thin ...

In early May 2026, Pfizer reported first-quarter revenue of US$14.45 billion and net income of US$2.69 billion, with earnings ...

NEW YORK, N.Y. — Pfizer announced Wednesday that data shows a third dose of its COVID-19 vaccine can “strongly” boost protection against the highly transmissible delta variant. The pharmaceutical and ...

The ongoing Phase 3 clinical trial of Pfizer/BioNTech's coronavirus vaccine confirms its protection lasts at least six months after the second dose, the companies said Thursday. The companies can now ...

Pfizer's vaccine against respiratory syncytial virus maintained protection for older adults across two full seasons of the disease in a late-stage clinical trial. The shot's protection declined from ...

Pfizer is an over-100-year-old drug company going through a rough patch, which has happened before.

The pharmaceutical outfit has taken a savvy step forward. Now it just needs to repeat the process a few more times.

NEW YORK - Pfizer on Wednesday shared data about a third dose of its COVID-19 vaccine that suggests it "strongly" boosts protection against the more contagious delta variant of the coronavirus, which ...

TRENTON, N.J. (AP) — Drugmaker Pfizer Inc. said Tuesday that a new patent on one of its top drugs, anti-inflammatory painkiller Celebrex, extends its U.S. patent protection by 18 months, potentially ...

A single dose of Pfizer's vaccine was 77.8% effective against more severe lower respiratory tract illness with three or more symptoms through a second season, down from the 88.9% efficacy following ...